Last update 25 Jan 2026

JV-213

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
JV 213, JV213
Target
CD79B
Action
modulators
Mechanism
CD79B modulators(B-cell antigen receptor complex-associated protein beta chain modulators), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesInfectious Diseases+ [2]
Active Indication
Burkitt LymphomaDiffuse Large B-Cell LymphomaHigh grade B-cell lymphoma+ [1]
Inactive Indication-
Originator Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with JV-213
NCT05773040
/ RecruitingPhase 1IIT
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
100 Clinical Results associated with JV-213
Login to view more data
100 Translational Medicine associated with JV-213
Login to view more data
100 Patents (Medical) associated with JV-213
Login to view more data
100 Deals associated with JV-213
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Burkitt LymphomaPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
14 Apr 2023
Diffuse Large B-Cell LymphomaPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
14 Apr 2023
High grade B-cell lymphomaPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
14 Apr 2023
Marginal Zone B-Cell LymphomaPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
14 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free